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&p.1:Abstract. [90Y]DOTA-DPhe1-Tyr3-octreotide ([90Y]-
SMT487) has been suggested as a promising radiothera-
peutic agent for somatostatin receptor-expressing tu-
mours. In order to quantify the in vivo parameters of this
compound and the radiation doses delivered to healthy
organs, the analogue [86Y]DOTA-DPhe1-Tyr3-octreotide
was synthesised and its uptake measured in baboons us-
ing positron emission tomography (PET). [86Y]DOTA-
DPhe1-Tyr3-octreotide was administered at two different
peptide concentrations, namely 2 and 100 µg peptide per
m2 body surface. The latter concentration corresponded
to a radiotherapeutic dose. In a third protocol
[86Y]DOTA-DPhe1-Tyr3-octreotide was injected in con-
junction with a simultaneous infusion of an amino acid
solution that was high in L-lysine in order to lower the
renal uptake of radioyttrium. Quantitative whole-body
PET scans were recorded to measure the uptake kinetics
for kidneys, liver, lung and bone. The individual abso-
lute uptake kinetics were used to calculate the radiation
doses for [90Y]DOTA-DPhe1-Tyr3-octreotide according
to the MIRD recommendations extrapolated to a 70-kg
human. The highest radiation dose was received by the
kidneys, with 2.1–3.3 mGy per MBq [90Y]DOTA-DPhe1-
Tyr3-octreotide injected. For the 100 µg/m2 SMT487
protocol with amino acid co-infusion this dose was
about 20%–40% lower than for the other two treatment
protocols. The liver and the red bone marrow received
doses ranging from 0.32 to 0.53 mGy and 0.03 to
0.07 mGy per MBq [90Y]DOTA-DPhe1-Tyr3-octreotide,
respectively. The average effective dose equivalent
amounted to 0.23–0.32 mSv/MBq. The comparatively
low estimated radiation doses to normal organs support
the initiation of clinical phase I trials with [90Y]DOTA-
DPhe1-Tyr3-octreotide in patients with somatostatin re-
ceptor-expressing tumours.
&kwd:Key words: Yttrium-86 – Yttrium-90 – Octreotide – Po-
sitron emission tomography – Dosimetry
Eur J Nucl Med (1999) 26:358–366
Introduction
[90Y]DOTA-DPhe1-Tyr3-octreotide ([90Y]SMT487) is a
radiotherapeutic somatostatin analogue that has the ca-
pability to induce shrinkage and even complete remis-
sion of somatostatin receptor-expressing tumours, as
demonstrated in animal experiments [1]. The pharmaco-
kinetics and the biodistribution of this compound were
previously evaluated in rodents by counting the activity
accumulated in each organ after the animals had been
sacrificed. Organ distributions of [111In]DOTA-DPhe1-
Tyr3-octreotide in rats bearing a pancreatic tumour were
reported [2]. A first clinical case report on the therapeu-
tic efficacy of [90Y]DOTA-DPhe1-Tyr3-octreotide was re-
cently published [3, 4].
The aim of this study was to evaluate the radiation
dosimetry of [90Y]DOTA-DPhe1-Tyr3-octreotide in pri-
mates prior to clinical trials with [90Y]DOTA-DPhe1-
Tyr3-octreotide. The determination of the radiation doses
requires the measurement of the uptake kinetics of
[90Y]DOTA-DPhe1-Tyr3-octreotide. As 90Y is a pure b –-
emitting isotope without accompanying g -radiation it
hardly allows quantitative evaluation from outside the
body. In the past only estimates of the quantitative up-
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take kinetics of 90Y radiopharmaceuticals and of the re-
sulting individual human radiation doses have been re-
ported, based on approaches such as (a) extrapolating
pharmacokinetic data measured ex vivo in animals to hu-
mans; (b) using measurements of urinary excretion and
blood clearance in humans to draw conclusions as to
whole-body radiation doses [5, 6]; (c) measuring human
uptake kinetics by means of bremsstrahlung registration
[7–10]; (d) substituting 90Y by g -emitting isotopes such
as 87Y or 88Y and performing measurements by means of
g -scintigraphy [11]; or (e) extrapolating from pharmaco-
kinetic data of chemically similar indium-111 radiophar-
maceuticals for the dosimetric calculation of the 90Y ra-
diopharmaceuticals [12–17]. As regards approach (e),
differences in the biodistribution between 111In and 90Y-
labelled antibodies were recently reported [18], these
differences possibly being due to the different in vivo
stabilities of the chemically different co-ordination com-
pounds.
While all these imaging approaches provide qualita-
tively relevant data they are less appropriate to provide
quantitative uptake data. However, it is the inherent ad-
vantage of positron emission tomography (PET) to as-
sess the uptake kinetics for individual organs quantita-
tively in vivo. This approach was already successfully
applied to analyse the pharmacokinetics of yttrium-90
radiopharmaceuticals in humans, using the positron-
emitting isotope yttrium-86 (T1/2= 14.74 h, 33% b +) as
isotopic surrogate [19,20]. Consequently, we regarded
the use of [86Y]DOTA-DPhe1-Tyr3-octreotide and PET to
be the most authentic quantitative approach to measure
the pharmacokinetics of [90Y]DOTA-DPhe1-Tyr3-octreo-
tide in baboons as a prerequisite for the calculation of
radiation doses caused by the [90Y]DOTA-DPhe1-Tyr3-
octreotide analogue. At the time the study was designed,
[90Y]DOTA-DPhe1-Tyr3-octreotide was not yet approved
for human use. This confined us to the presented compa-
rably limited study protocol in primates.
Materials and methods
Synthesis of [86Y]DOTA-DPhe1-Tyr3-octreotide. &p.2:The 86Y was pro-
duced as described previously [21, 22] at the Jülich compact cy-
clotron CV28. DOTA-DPhe1-Tyr3-octreotide (SMT487) was syn-
thesised at Novartis Pharma, Switzerland [23]. The chemical
structure is illustrated in Fig. 1.
A stock solution of 1.47 mM SMT 487 in H2O/HAcconc/MeOH
(100/1/1) was prepared. Depending on the experiment, small
amounts of the stock solution were added to defined portions of
0.15 M NH4OAc solution, pH 4.5, containing 0.3% bovine serum
albumin (BSA). After transferring about 1–3 mCi of the no-carrier-
added (n.c.a.) 86Y in 0.15 M a -hydroxyisobutyric acid, the vial was
closed and the reaction mixture was heated for 15 min at 100°C in
a water bath. After complexation had been completed, 1 µl of the
reaction mixture was added to 100 µl of the labelling buffer.
Quality control. &p.2:Five microlitres of this solution was mixed with
100 µl of a 4 mM DTPA solution, pH 4.5, and quality control was
performed using high-performance liquid chromatography
(HPLC) [Nucleosil RP C-18, 5 µ; buffer A: 0.025 M NH4OAc,
pH 4.5; buffer B: MeCN/H2O/1 M NH4OAc, pH 4.5 (60/40/2);
1.2 ml/min] with a gradient of 0–15 min; 0–60% B, 15–20 min
60% B, 20–25 min 60–80% B (Table 1). Elution profiles were re-
corded by UV as well as by radioactivity detectors. Under these
conditions two peaks were found with retention times of
3.6±0.2 min (86Y-DTPA) and 13.1±0.2 min ([86Y]DOTA-DPhe1-
Tyr3-octreotide).
The labelling was highly effective, with typical labelling yields
of >98.5%. Specific activities of 28 GBq/µM and 0.5 GBq/µM
were reached for the two labelling conditions of 2 and 100 µg
SMT487 per m2 body surface, respectively. Prior to the adminis-
tration to the baboons the reaction mixture was diluted with a
buffer solution (10 mM HEPES, pH 7.6; 1% BSA) to a final injec-
tion volume of 500 µl per monkey. For each protocol, the baboons
received 10–40 MBq [86Y]DOTA-DPhe1-Tyr3-octreotide.
Animals. &p.2:Two male and one female baboons (Papio hamadryas)
took part in this study. Their ages were between 3 and 4 years and
the weights 12.4 kg, 9.1 kg and 7.9 kg. The baboons came from
the German primate centre in Göttingen and stayed in the For-
schungszentrum Jülich for 4 weeks. The principles of laboratory
animal care were followed.
Treatment groups. &p.2:All animal experiments were carried out ac-
cording to the Deutsches Tierschutzgesetz. In particular, only one
Fig. 1. Structure of DOTA-DPhe1-
Tyr3-octreotide (SMT487) &/fig.c:
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anaesthetic procedure per week was permissible, lasting for only
some hours per experiment and animal. Therefore the same ani-
mal could not be imaged several times over a period of 24 h. It
was, therefore, the strategy of the study to analyse one and the
same animal at identical periods post injection (p.i.) of the tracer
and to compare the biokinetic data for three different experimental
protocols. Each experimental protocol was performed at 1 week,
the three different experimental protocols thus being carried out
within three consecutive weeks. For each protocol the three ba-
boons (A, B, C) were injected nearly simultaneously, but mea-
sured at different time points p.i.. Table 1 gives an overview of the
different treatment protocols.
In the first and second weeks, [86Y]DOTA-DPhe1-Tyr3-octreo-
tide was administered at two different compositions with regard to
the concentration of the peptide, namely 2 and 100 µg SMT487
per m2 body surface. The 100 µg SMT487 per m2 dose reflects the
peptide dose in a radiotherapeutic dose of [90Y]DOTA-DPhe1-
Tyr3-octreotide, whereas the 2 µg SMT487 per m2 dose corre-
sponds to the diagnostic dose range of the peptide of <10 µg/m2 as
used for 111In-OctreoScan. An average body surface of a baboon
of about 0.4 m2 was assumed. Therefore, in the experiments using
100 µg/m2 SMT487 the injected solution contained 40 µg of
SMT487 while in the experiment using 2 µg/m2 SMT487 the in-
jected solution contained 0.8 µg SMT487, in both cases in 500 µl
buffer.
In the third-week protocol the 100 µg/m2 SMT487 dose was
administered together with an amino acid solution (Nephroplas-
mal N7%) that was high in L-lysine (8 g/l). We assumed that the
pharmacokinetics of L-lysine are similar to those of small peptides
(or even faster). From rodent experiments it was known that high
doses of L-lysine (2 g/kg in mice) were required [24] and that the
blood clearance of radiolabelled SMT 487 was fast. Since the du-
ration of the anaesthesia in primates was restricted, the amino acid
infusion was maintained for 30 min, starting 15 min before and
ending 15 min after the administration of [86Y]DOTA-DPhe1-Tyr3-
octreotide with an infusion rate of 0.5 ml/min.
Anaesthesia. &p.2:General anaesthesia was induced using ketamine
(10 mg/kg, i.m.). Salivary secretion was reduced by intramuscular
glycopyrrolate (Robinul 0.02 mg/kg). Prior to intubation
2–3 mg/kg methohexital was injected intravenously. During the
transportation to the PET scanner the anaesthesia was maintained
by further bolus injections of methohexital (2 mg/kg i.v.). During
the PET measurement anaesthesia was maintained at a constant
level by inhalation anaesthesia (isoflurane, nitrous oxide and oxy-
gen). The animals were monitored by EKG, pulse oxymetry,
capnography and invasive and non-invasive measurements of
blood pressure. After the PET measurements the animals were
transported back to their cages and continuously supervised until
they woke up.
Blood and urine measurements. &p.2:Blood samples were taken from
the baboons before the injection as well as at 24 h and at 4 weeks
post injection of [86Y]DOTA-DPhe1-Tyr3-octreotide and subjected
to conventional clinical chemistry analysis. Differential blood
counts, measures of kidney function (creatinine, urea, uric acid,
cholesterol, triglycerides, bilirubin, total protein, Fe, Na, K, Ca,
Cl, P), liver enzymes (aspartate aminotransferase, alanine, trans-
aminase, g -glutamyl transpeptidase and alkaline and acidic phos-
phatases) and blood sugar were determined. The blood cell counts
in the baboons were normal for all time points, showing no major
differences from the values as measured in normal males/females.
Simultaneously with the PET measurements, blood was sam-
pled from the femoral artery at 0.5, 1, 1.5, 2, 4, 6, 10, 15, 30, 60
and 90 min p.i. for baboon A, at 5 and 6.5 h for baboon B and at
24 or 17 h p.i. for baboon C. Aliquots of each of these samples
were subjected to radiochemical analysis (see below). The radio-
activity in the blood pool at each time was calculated from the
measured activity per unit volume in the blood samples and the
estimated blood volume as 7% of total body weight. The blood-
activity curves were fitted by two-exponential functions from 0 to
90 min p.i. Later blood data of baboons B and C were not includ-
ed in these fits because of possible errors due to the inter-individ-
ual variabilty. The time constants resulting from the fits were con-
verted into elimination half-lifes T1/2 a and T1/2 b , describing a fast
and a slow elimination phase for the kinetics measured in baboon
A, i.e. covering the blood clearance kinetics up to 1.5 h post injec-
tion.
Individual blood radioactivity data are expressed as %ID/ml.
Any individual errors and significance tests are included because
of the one-animal-per-experiment character of the study. However,
individual experimental errors can be derived for every individual
measurement. The uptake values given in %ID for kidney, liver
and skeleton are derived from PET measurements with individual
errors of less than 15%. The blood clearance and urinary excretion
kinetics were calculated by g -spectroscopy with average errors of
less than 10% for time points up to 5 h p.i. and less than 15% at
24 (or 17) h p.i. Because these values became the basis for further
calculations, elimination half-life errors are of the same order of
magnitude.
Urine was collected via catheter (baboons A and C) or by peri-
odically pressing the bladder (female baboon B) only during the
period of the corresponding PET measurements. Radioactivity in
1-ml aliquots of urine was measured by g -spectrometry. The urine
could not be collected continuously over the whole period of inves-
tigation, i.e. for one entire day after injection, because this would
have required catheterisation of the animal under repeated anaes-
thesia, which is not allowed by the Deutsches Tierschutzgesetz.
Stability of [86Y]DOTA-DPhe1-Tyr3-octreotide in vivo. &p.2:Blood sam-
ples were centrifuged at 4300 rpm for 20 min without clotting
Baboon Body PET Activity injected (MBqa)
weight measurement
(kg) (h p.i.) 100 µg/m2 100 µg/m2 SMT487 + 2 µg/m2
SMT487 amino acid infusion SMT487
A (male) 12.4 0–1.5 38.3 17.5 14.6
B (female) 9.1 5 27.1 22.6 9.9
C (male) 7.9 24 or 17b 27.1 23.4 16.3b
a 1 MBq = 27 µCi
b PET measurement for baboon C in the 2 µg/m2 SMT487 protocol at 17 h instead of 24 h &/tbl.b:
Table 1. Treatment groups and protocols &/tbl.c:&tbl.b:
protection. The supernatant serum was treated with a mixture of
MeOH/MeCN (1/1) and again centrifuged to separate the precipi-
tated serum proteins. Finally, 100 µl of the supernatant protein-
free solution was mixed with 50 µl of a 4 mM DTPA solution,
pH 4.5, and analysed by HPLC for quality control. The
[86Y]DTPA and the [86Y]DOTA-DPhe1-Tyr3-octreotide fractions
were collected and the amount of the two fractions was deter-
mined in percent of injected activity. Blood platelets, serum pro-
teins and the collected fraction were assayed by an automatic
NaI(Tl) counter. Urine samples were taken 60 min, 90 min, 5 h
and 17 h p.i. Fifty microlitres of a 4 mM DTPA solution was add-
ed to 100–200 µl of the urine. This mixture was analysed by
HPLC.
PET measurements. &p.2:The PET measurements were performed with
a GE scanner 4096 plus, which records 15 image planes simulta-
neously within an axial field of view of 10.5 cm [25]. Prior to the
emission measurements, transmission scans were acquired over
10 min using a rotating line source filled with germanium-68, so
that measured attenuation correction could be applied. Each series
of emission scans was started with an injection of 10–40 MBq
[86Y]DOTA-DPhe1-Tyr3-octreotide. In baboon A dynamic PET
scans were acquired after tracer injection for 90 min. During a re-
petitive sequence of three scans of 2–5 min each the scanner was
positioned over the head, the abdomen and the pelvis. The head
position was included to look for possible accumulation of the
tracer in the pituitary. The abdominal position included the liver
and kidneys, while the pelvic position included the caudal parts of
the liver, the kidneys and the bladder. At 1 h a continuous whole-
body scan ranging from the head to the pelvis was done so that the
upper and lower thorax could also be imaged. This sequence of
PET measurements was performed in animal A in each week.
Baboon B was measured at about 5 h after injection. In this
case the whole-body transmission measurement was followed by a
whole-body emission scan, again ranging from the head to the
pelvis, so that the bladder was included as well. The same proce-
dure was repeated in baboon C at 17 h or 24 h p.i.
Image reconstruction. &p.2:The resolution of the PET images recon-
structed with filtered backprojection after attenuation correction
was about 7 mm. Using all 75 image planes of the whole-body
scans, reprojected body views [19] were calculated in order to de-
lineate areas with enhanced tracer uptake. Regions of interest
(ROIs) were placed over areas where distinct activity concentra-
tions became visible, i.e. over the kidneys, liver, spine, humerus
and bladder. All regions were defined in at least three adjacent im-
ages. By applying all ROIs to the dynamic image data, decay-cor-
rected time-radioactivity curves were derived in the unit of activi-
ty concentration, i.e. kBq/ml.
The ROI over the liver was marked within the organ. For kid-
neys and bladder the ROI borders coincided with the organs’ bor-
ders estimated from the activity distribution. ROIs over the bone
were defined using an isocontour level of 60% of the image maxi-
mum. In addition all transverse slices of the whole-body scans at
5 h and 24 or 17 h p.i. were evaluated as described above to obtain
the cumulative whole-body activity. In the scans of baboon A the
pituitary could just be identified, but was overlaid with so much
noise that no attempt was made at analysis.
To determine the whole-body activity, the whole-body scans
recorded at 4 h and 24 h or 17 h were directly evaluated. In all
transverse slices, ROIs were defined comprising the body shape as
visible in the transmission scan. The product of ROI mean (unit
kBq/cm3) and the ROI area (unit cm2) was multiplied by the slice
thickness of 6.4 mm to obtain the overall radioactivity of 86Y in
each slice. The summation of the activity of all slices resulted in
the whole-body activity.
Radiation dose calculations. &p.2:In order to calculate estimates for
the radiation doses of the therapeutic [90Y]DOTA-DPhe1-Tyr3-oc-
treotide, the decay-corrected time-activity curves of the 86Y-la-
belled analogue for the organs with visible radioactivity uptake
and for the remainder of the body were first determined. The re-
sulting time-activity curves were extrapolated until seven half-
times of 90Y (i.e. 448 h) and then multiplied with the decay func-
tion of 90Y, so that the residence times could be calculated by in-
tegration and by relating the integral to the injected activity. In or-
der to obtain the activity uptake of the single organs the radioac-
tivity concentration data measured by PET had to be multiplied
by the organ volumes. In the case of kidneys and the liver the vol-
umes were derived from the areas of ROls placed along the bor-
ders of the organs in all image planes in which the organ was visi-
ble. This approach was not possible for the skeleton; its volume
was estimated from the volume of the human skeleton by scaling
it with the ratio of the baboon’s weight and the 70 kg of the refer-
ence man [26].
As already explained, it was not possible to scan one animal
continuously over 24 h or three times within 24 h. Therefore, the
kinetic data of [86Y]DOTA-DPhe1-Tyr3-octreotide had to be com-
bined from all three baboons; this procedure, however, neglects
possible variations among the animals. For this reason a conserva-
tive exponential function estimation was applied. Instead of fitting
the slowly decreasing (decay-corrected) kinetics for liver and kid-
neys we assumed a constant tracer uptake, calculated as the aver-
age of the uptake data at 1 h, 5 h and 24 h p.i. (or 17 h for the
100 µg/m2 [86Y]DOTA-DPhe1-Tyr3-octreotide injection).
In contrast to the kidneys and the liver a considerable release
of radioactivity from the bone was observed. Consequently, two-
exponential fits were applied to describe its uptake kinetics. Using
the time-activity data of the whole body as shown in Table 3, the
residence time for the urinary bladder contents was determined
according to the model suggested by Cloutier et al. [27]. The resi-
dence time for the remainder of the body was calculated as the
difference between the whole-body activity and the sum of the ra-
dioactivity found in liver, kidneys and bone.
After having determined the residence times for kidneys, liver,
bone, bladder and remainder of the body, the radiation doses for a
70-kg adult were calculated by means of the MIRDOSE3 program
[28]. The residence time calculated for total bone was equally at-
tributed to cortical and trabecular bone. The bladder dose was de-
termined assuming voiding intervals of 1 h or 0.1 h. However, 1 h
is regarded as the shortest feasible interval for discrete voiding.
The dose to the bladder might be further reduced by catheterisat-
ion. For the purpose of the MIRDOSE3 calculation the voiding in-
terval of 0.1 h is considered as equivalent to catheterisation.
Results and discussion
Blood pharmacokinetics
Individual blood radioactivity data for [86Y]DOTA-
DPhe1-Tyr3-octreotide are summarised in Table 2. The
simultaneous infusion of amino acids resulted in an
about 1.5-fold decrease in blood pool activity during the
first hour p.i. when compared with the administration of
[86Y]DOTA-DPhe1-Tyr3-octreotide without co-infusion
of amino acids. Within this period more than 90% of the
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injected [86Y]DOTA-DPhe1-Tyr3-octreotide was cleared
from the circulation after all three treatment protocols.
At later time points a greater percentage remained in the
blood after the 2 µg/m2 dose than after either of the
100 µg/m2 doses.
For all three treatment protocols the clearance of
[86Y]DOTA-DPhe1-Tyr3-octreotide from blood was bi-
phasic during the first 90 min p.i. In the initial rapid
phase the elimination half-life T1/2 a was 0.42 min and
0.95 min for 100 µg/m2 without and with amino acid in-
fusion, respectively, and 2.4 min for 2 µg/m2. The sec-
ond elimination phase was similar in the case of
100 µg/m2 both with and without amino acid infusion, at
20 min and 23 min, respectively. This slow elimination
half-life T1/2 b was again slower, at 58 min, in the case of
the 2 µg/m2 treatment protocol. Thus, the elimination of
[86Y]DOTA-DPhe1-Tyr3-octreotide from the blood was
about 2.5 times slower when low peptide amounts
(2 µg/m2) were used. The percentages of the first expo-
nential component were 81%, 66% and 73% for the pro-
tocols with 100 µg/m2 with and without amino acid and
with 2 µg/m2, respectively. The corresponding percent-
ages of the second exponential component were 19%,
34% and 27%, respectively.
Urinary excretion
The individual urinary excretion kinetics of [86Y]DOTA-
DPhe1-Tyr3-octreotide in the baboons are shown in Fig. 2
as %ID/ml urine. The rate of excretion peaked at about
1 h p.i. at 0.76 %ID/ml, when [86Y]DOTA-DPhe1-Tyr3-
octreotide was administered without co-infusion of ami-
no acids. After administration of 100 µg/m2 with simul-
taneous amino acid infusion, however, the highest excre-
tion rate was observed at 1.5 h p.i. This may point to a
lower retention of the peptide within the kidneys owing
to the interaction of the amino acids (preferentially L-ly-
sine) with the peptide uptake mechanism located in the
kidney cortex [29]. The same observation was made at
later time points (e.g. 5 h p.i.) and in particular at about
1 day p.i.. At 24 h (or 17 h) p.i. the urinary excretion
rate decreased to very low values of 0.007% ID/ml,
0.1% ID/ml and 0.0003% ID/ml for the protocols with
100 µg/m2, with 100 µg/m2 including simultaneous ami-
no acid infusion and with 2 µg/m2 [86Y]DOTA-DPhe1-
Tyr3-octreotide, respectively. This indicates the impor-
tance of the infusion of the amino acid simultaneously
with the injection of the radiolabelled octreotide ana-
logue.
Cumulatively, about 17% ID and 33% ID of
[86Y]DOTA-DPhe1-Tyr3-octreotide was excreted within
1.5 h p.i. by the baboons treated with 100 µg/m2 without
and with simultaneous amino acid infusion, respectively.
After administration of 2 µg/m2 [86Y]DOTA-DPhe1-Tyr3-
octreotide 16% ID was excreted within 1.5 h p.i.
From the whole-body evaluation it is concluded that
at 5 h p.i. 80%–84% and at 24 (or 17) h p.i. 93%–95%
of the injected activity is excreted probably mainly via
the urine and perhaps to a smaller amount via the faeces
(Table 3). The different routes of excretion could not be
controlled with the animals awake in their cages.
Table 2. Blood radioactivity of [86Y]DOTA-DPhe1-Tyr3-octreotide
([86Y]SMT487) in individual baboons &/tbl.c:&tbl.b:
Baboon Time p.i Blood radioactivity (% ID/ml)
100 µg/m2 100 µg/m2 2 µg/m2
SMT487 SMT487 SMT487
+ amino acid
infusion
A 0.5 min 0.101 0.046 0.034
A 1 min 0.049 0.041 0.037
A 1.5 min 0.054 0.033 0.035
A 2 min 0.043 0.026 0.027
A 4 min 0.028 0.019 0.017
A 6 min 0.026 0.020 0.016
A 10 min 0.019 0.017 0.015
A 15 min 0.017 0.010 0.009
A 30 min 0.013 0.006 0.007
A 60 min 0.008 0.005 0.006
A 90 min 0.004 0.004
B 5 h 0.003 0.003
B 6 h 0.002 0.005
C 24 (17) h 0.00004 0.0001 0.003
&/tbl.b:
Fig. 2. Rate of urinary excretion of [86Y]DOTA-DPhe1-Tyr3-oct-
reotide ([86Y]SMT487) in percent of the injected dose (%ID) per
ml urine in individual baboons. All animals received 10–40 MBq
[86Y]DOTA-DPhe1-Tyr3-octreotide per baboon containing differ-
ent peptide concentrations. aai, Tracer injection with simulta-
neous amino acid co-infusion &/fig.c:
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Stability analysis
The [86Y]DOTA-DPhe1-Tyr3-octreotide was stable in vi-
tro up to 12 h after labelling. Radiochemical analysis of
the serum water fractions showed that at 1.5 h >95% and
at 5 h >90% of the remaining activity corresponded to
the intact [86Y]DOTA-DPhe1-Tyr3-octreotide. Negligible
amounts of the tracer were bound to blood cells. The in
vivo stability of [86Y]DOTA-DPhe1-Tyr3-octreotide in
the urine was >99% under all treatment protocols up to
90 min p.i. and >97.5% up to 5 h p.i.
Pharmacokinetics of [86Y]DOTA-DPhe1-Tyr3-octreotide
as measured with PET
In the whole-body images predominantly the bladder
and kidneys were visible, with faint representation of the
liver and skeleton, especially the joints (Fig. 3). The
quantitative [86Y]DOTA-DPhe1-Tyr3-octreotide accumu-
lation in percent of the injected activity in kidneys, liver
and skeleton is summarised in Table 3. In the liver a pri-
mary uptake of about 4% of the injected activity was
found, which rapidly decreased to 1.5%–2%ID for the
100 µg/m2 protocol both with and without amino acid in-
fusion, whereas the comparable values for the 2 µg/m2
dose were slightly above 2%ID.
The kidneys are the organ with the highest activity
concentration of [86Y]DOTA-DPhe1-Tyr3-octreotide. The
uptake ranged from 3.5%–2.1%/ID after 3–30 min p.i.
and decreased with time. Up to 1 h p.i. this uptake was
higher after administration of 100 µg/m2 with amino ac-
id co-infusion compared with the other protocols. This
effect may reflect the higher clearance rate of the radio-
ligand during the amino acid infusion. However, this up-
take kinetics is more correlated to an enhanced renal
blood flow as a consequence of the amino acid infusion
[30, 31]. In the present study, kidney function was stim-
ulated 15 min before injection, resulting in a much high-
er tubular filtration rate in the experimental protocol
with amino acid co-infusion. Consequently, the kidney
uptake between 10 and 40 min p.i. was about twice the
uptake measured for the two protocols without amino
acid infusion. At about 30 min after the amino acid infu-
sion was stopped (15 min p.i.) and the kidney uptake fell
to a more “normal” level, comparable to that with the
two other protocols. This seems to have occurred in par-
allel with to the normalisation of the renal blood flow.
After 5 h the activity accumulation had dropped further
to levels about half those measured for the two other
protocols without amino acid infusion (Table 3). This re-
sult is interpreted as an effect of the blockade of binding
places in the kidney cortex by cationic amino acid infu-
sion. This, consequently, becomes responsible for the
lower radiation dose (see below).
The activity distribution to the kidneys did not mark-
edly decrease at about 1 day p.i. in any of the three ex-
perimental protocols. Whereas in the early images radio-
activity was seen in the renal pelvis, in the late images it
was mainly found in the renal cortex. This is illustrated
in the transverse PET images (Fig. 4). Upon administra-
tion of [86Y]DOTA-DPhe1-Tyr3-octreotide containing
100 µg/m2 of the peptide with amino acid co-infusion
the highest rate of activity accumulation in the bladder
as derived from the PET measurements was found with-
in the first hour p.i.. A lower influx rate was found in the
2 µg/m2 treatment protocol and in the 100 µg/m2 proto-
col without amino acid co-infusion.
Data for activity distribution to the bone were evaluat-
ed at the time of the whole-body scans. The total skeletal
Table 3. [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) accumulation in total organs (kidneys, liver and skeleton) and whole-body ac-
tivity of individual baboons measured in percent of injected activity &/tbl.c:&tbl.b:
Time p.i. Activity ( %ID)
100 µg/m2 SMT487 100 µg/m2 SMT487 2 µg/m2 SMT487
+ amino acid infusion
Kid- Liver Skele- Whole Kid- Liver Skele- Whole Kid- Liver Skele- Whole
neys ton body neys ton body neys ton body
0 min 0 0 0 100 0 0 0 100 0 0 0 100
3 min 2.4 3.2 2.9 3.0 2.1 3.7
10 min 1.8 2.0 2.7 2.0 1.6 2.4
15 min 1.5 1.7 3.5 2.0 1.5 2.0
25 min 1.5 1.5 2.4 1.6 1.6 2.0
40 min 1.4 1.3 3.1 1.5 1.6 1.8
50 min 1.2 1.3 2.2 1.7 1.8 2.0 1.7 1.6 1.5
80 min 1.2 1.1 1.7 1.5 1.6 1.5
95 min 1.1 1.0 83 1.4 1.3 70 1.5 1.4 84
ca. 5 h 2.0 1.6 0.9 16 1.2 1.6 1.2 16 2.4 2.6 1.4 20
24 (17) h 1.6 0.8 0.6 7 1.2 0.8 0.4 5 1.7 1.5 1.0 7.4
&/tbl.b:
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uptake was 1.5%–2.2%ID for the three treatment proto-
cols at 50 min p.i. (Table 3). The activity in the skeleton
decreased to about 0.9%–1.4%ID and 0.4%–1.0%ID at
5 h p.i. and 24 (or 17) h p.i., respectively. The residence
times for these organs are summarised in Table 4.
The distribution of [86Y]DOTA-DPhe1-Tyr3-octreo-
tide activity to the spleen of the primates was not higher
than the background from the abdomen. This is in con-
trast to the biodistribution and dosimetry found after ad-
ministration of 111In-OctreoScan to patients [32]. How-
ever, it is in line with the distribution of [111In]DOTA-
DPhe1-Tyr3-octreotide to the primate spleen [unpub-
lished results].
Radiation doses
Due to study design, the main emphasis was on the com-
parison of biokinetic data for one and the same animal,
but for three different experimental protocols. Because
not only one and the same animal but also identical mea-
surement periods were considered, errors in comparison
of the biokinetic data (blood clearance, urinary excre-
tion, individual organ uptake kinetics) are negligible. For
the first baboon A, i.e. for the early period up to 1.5 h
p.i., the increasing effect of amino acid co-infusion on
the tracer accumulation in the kidneys could be clearly
shown. On the other hand, animal B was used to com-
1 h p.i.
A B C
5 h p.i. 24 h p.i.
Fig. 3. Whole-body PET scans
of baboons A, B and C injected
with 10–40 MBq [86Y]DOTA-
DPhe1-Tyr3-octreotide per ba-
boon containing 100 µg/m2 pep-
tide without simultaneous amino
acid co-infusion, recorded at 1 h
p.i. (baboon A), 5 h p.i. (baboon
B) and 24 h p.i. (baboon C). &/fig.c:
1 h p.i.
baboon A
24 h p.i.
baboon C
Fig. 4. Transverse PET scans of
the kidneys of baboons A and C
injected with 10–40 MBq
[86Y]DOTA-DPhe1-Tyr3-octreo-
tide per baboon containing
100 µg/m2 peptide without simul-
taneous amino acid co-infusion,
recorded at 1 h p.i. (baboon A)
and 24 h p.i. (baboon C) &/fig.c:
Table 4. Residence times of [86Y]DOTA-DPhe1-Tyr3-octreotide
([86Y]SMT487) in kidneys, liver, lung, bone, urinary bladder and
remainder of the body in baboons &/tbl.c:&tbl.b:
Organ Residence times (h)
100 µg/m2 100 µg/m2 2 µg/m2
SMT487 SMT487 SMT487
+ amino acid 
infusion
Kidneys 1.56 1.17 1.83
Liver 1.14 1.20 1.88
Lung 0.16 0.08 0.14
Bone 0.33 0.25 0.43
Urinary bladdera 0.27 0.45 0.42
Remainder of the body 5.9 3.1 6.4
a 1 h voiding interval &/tbl.b:
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pare organ uptakes for medium time points, i.e. about
5 h p.i; in this case the reduced tracer uptake in the kid-
neys could obviously be compared for the three different
experimental protocols.
Quantification was important for the estimated radia-
tion dose. In this case the organ activity accumulation
was averaged for the time points of 95 min, 5 h and 24
(17) h for the three baboons. Thus, inter-individual
changes could not significantly affect the calculations.
As stated, the resulting values thus reflect maximum es-
timated radiation doses.
The radiation doses estimated for the therapeutic
[90Y]DOTA-DPhe1-Tyr3-octreotide are listed in Table 5.
The critical organs are the kidneys, with values be-
tween 2.1 and 3.3 mGy per MBq injected [90Y]DOTA-
DPhe1-Tyr3-octreotide. The bladder receives average
doses of 0.6 mGy/MBq (voiding interval 1 h). The aver-
age effective dose equivalent is 230–320 µSv/MBq. The
100 µg/m2 protocol with amino acid infusion resulted in
a kidney dose about 20% less (230 µSv/MBq) than that
of the same protocol without amino acid infusion
(280 µSv/MBq). The protocol with the lower peptide
amount present in the radioligand preparation (2 µg/m2)
resulted in increased radiation doses. This might have
been due to the higher specific activity in this prepara-
tion.
Conclusion
Using the b +-emitting 86Y as a substitute for b –-emitting
90Y and in vivo PET measurements the pharmacokinet-
ics and radiation doses of [90Y]DOTA-DPhe1-Tyr3-oct-
reotide were determined in non-human primates. Al-
though no individual errors and significance tests were
considered because of the one-animal-per-experiment
character of the study, some conclusions may be derived.
The octreotide analogue [86Y]DOTA-DPhe1-Tyr3-octreo-
tide is highly stable in vivo both in serum and in urine.
Binding of [86Y]DOTA-DPhe1-Tyr3-octreotide to blood
cells and serum proteins is negligible. Rapid clearance
of intact [86Y]DOTA-DPhe1-Tyr3-octreotide from the
blood was observed.
As calculated for a 70-kg human, the highest radia-
tion dose will be delivered to the kidneys and was ex-
trapolated to amount to less than 3 mGy per MBq
[90Y]DOTA-DPhe1-Tyr3-octreotide injected with the
100 mg peptide per m2 body surface dose. Simultaneous
co-infusion of an amino acid solution that is high in cat-
ionic amino acids, e.g. L-lysine, will accelerate the
whole-body clearance of [86Y]DOTA-DPhe1-Tyr3-octreo-
tide and thereby lower the radiation dose to the kidneys
by about 20%. This effect is in accordance with the find-
ing of a reduction in kidney distribution of the radiodi-
agnostic octreotide analogue 111In-OctreoScan in pa-
tients after an amino acid infusion that is high in L-lysine
[33]. The reason for this may lie in the competition of
the peptide moiety of [86Y]DOTA-DPhe1-Tyr3-octreotide
for uptake into the renal cortex with the cationic amino
acids infused during radioligand administration.
Taken together, the high in vivo stability and the com-
paratively low estimated radiation doses to normal or-
gans are encouraging for the further evaluation of so-
matostatin receptor-targeted radiotherapy in patients us-
ing [90Y]DOTA-DPhe1-Tyr3-octreotide. A phase I trial is
now being conducted to utilise [90Y]DOTA-DPhe1-Tyr3-
octreotide ([90Y]SMT487) for endoradiotherapy, which
is preceded by PET studies using [86Y]DOTA-DPhe1-
Tyr3-octreotide ([86Y]SMT487).
&p.2:The assistance of M. Cremer and J. Füner in baboon care is ac-
knowledged. We thank G. Stöcklin, H.H. Coenen and the cyclo-
tron teams of the Institute for Nuclear Chemistry at the For-
schungszentrum Jülich. This work was supported in part by the
grants DFG Ro 985/2-1 and Ro 985/2-2.
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